This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Earnings Preview: J&J 1Q To Focus On Newest Drugs


TRENTON, N.J. (AP) â¿¿ Johnson & Johnson will highlight the recent approval of its first drug in the huge diabetes market, plus progress toward getting two other drugs approved, when it reports first-quarter results before the stock market opens Tuesday.

WHAT TO WATCH FOR: The world's biggest maker of health care products will focus on the March 29 U.S. approval of Invokana, known chemically as canagliflozin. The daily pill is the first drug in a new class of Type 2 diabetes medicines that work by increasing how much sugar is excreted via urine.

J&J's first entry in the multibillion-dollar medicine market fueled by the global diabetes epidemic, Invokana will complement its OneTouch and Vibe lines of all manner of diabetes devices. Executives should discuss plans for launching Invokana, including having sales reps for those diabetes devices promote it. It's awaiting approval in some other countries.

Chief Financial Officer Dominic Caruso will update J&J's 2013 profit forecast. He will note a charge of about 4 cents per share due to Venezuela's currency devaluation and likely discuss exchange rate effects.

J&J will note prostate cancer drug Zytiga got European Union approval in January for use earlier in treatment â¿¿ before chemotherapy.

J&J, based in New Brunswick, N.J., just applied for Food and Drug Administration approval of simprevir, its second drug for hepatitis C. That's another disease with a fast-growing market, as baby boomers infected decades ago finally get diagnosed with the silent liver-destroying disorder.

This week, the FDA granted a third breakthrough therapy designation for a cancer drug still in testing, ibrutinib. That's meant to speed up late-phase testing and review of the drug. J&J plans this year to seek approval for the drug as a treatment for mantle cell lymphoma.

Those positives are offset by a surge of litigation over allegedly faulty products, plus the company's continuing struggle to end an eye-popping streak of about three dozen product recalls. Most were nonprescription medicines, including Tylenol and Motrin. Reasons range from nauseating packaging smells to tiny glass and metal shards in liquid medicines. Some products are still off store shelves after three years, reducing revenue. The company is rebuilding one factory from the ground up and making other manufacturing improvements under an agreement with the FDA, hiking the tab.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.24 0.00%
FB $117.81 0.00%
GOOG $701.43 0.00%
TSLA $211.53 0.00%
YHOO $36.94 0.00%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs